Yoshino T - Search Results

1

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin.

Fontana E, Meyers J, Sobrero A, Iveson T, Shields AF, Taieb J, Yoshino T, Souglakos I, Smyth EC, Lordick F, Moehler M, Giraut A, Harkin A, Labianca R, Meyerhardt J, André T, Boukovinas I, Lonardi S, Saunders M, Vernerey D, Oki E, Georgoulias V, Ben-Aharon I, Shi Q. Fontana E, et al. Among authors: yoshino t. J Clin Oncol. 2021 Dec 20;39(36):4009-4019. doi: 10.1200/JCO.21.02008. Epub 2021 Nov 9. J Clin Oncol. 2021. PMID: 34752136 Free PMC article.

2

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H. Yoshino T, et al. Jpn J Clin Oncol. 2007 Sep;37(9):686-91. doi: 10.1093/jjco/hym091. Epub 2007 Aug 24. Jpn J Clin Oncol. 2007. PMID: 17720736

3

Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.

Machida N, Yoshino T, Boku N, Hironaka S, Onozawa Y, Fukutomi A, Yamazaki K, Yasui H, Taku K, Asaka M. Machida N, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2008 Oct;38(10):689-94. doi: 10.1093/jjco/hyn086. Jpn J Clin Oncol. 2008. PMID: 18845522

4

Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).

Ono A, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Yoshino T, Taku K, Kojima T. Ono A, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2009 May;39(5):332-5. doi: 10.1093/jjco/hyp018. Epub 2009 Mar 24. Jpn J Clin Oncol. 2009. PMID: 19318372

5

Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.

Yasui H, Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N. Yasui H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2009 May;39(5):315-20. doi: 10.1093/jjco/hyp014. Jpn J Clin Oncol. 2009. PMID: 19403734

6

Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.

Ikeda E, Kojima T, Kaneko K, Minashi K, Onozawa M, Nihei K, Fuse N, Yano T, Yoshino T, Tahara M, Doi T, Ohtsu A. Ikeda E, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2011 Aug;41(8):964-72. doi: 10.1093/jjco/hyr088. Epub 2011 Jul 7. Jpn J Clin Oncol. 2011. PMID: 21742654

7

Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.

Satake H, Yoshino T, Sasaki T, Bando H, Yoda Y, Ikematsu H, Kojima T, Fuse N, Zenda S, Doi T, Kaneko K, Ohtsu A. Satake H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2012 Sep;42(9):861-4. doi: 10.1093/jjco/hys093. Epub 2012 Jun 19. Jpn J Clin Oncol. 2012. PMID: 22717459

8

Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies.

Okano S, Tahara M, Zenda S, Fuse N, Yoshino T, Doi T, Kawashima M, Ogino T, Hayashi R, Ohtsu A. Okano S, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2012 Aug;42(8):691-6. doi: 10.1093/jjco/hys096. Epub 2012 Jul 3. Jpn J Clin Oncol. 2012. PMID: 22761254

9

Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.

Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Bando H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2012 Dec;42(12):1146-51. doi: 10.1093/jjco/hys160. Epub 2012 Oct 15. Jpn J Clin Oncol. 2012. PMID: 23071293

10

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Grothey A, et al. Among authors: yoshino t. Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177514 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,053 results

Search Page